This was a multicentre , randomised , double-blind , placebo-controlled , three-way cross-over , incomplete block study to evaluate UMEC 15.6 , 31.25 , 62.5 , and 125 g administered once daily ( QD ) , and UMEC 15.6 g and 31.25 g administered twice daily ( BID ) , over 7 days in patients with COPD .